California Peptide Research产品代理
简要描述：California Peptide Research提供客户的多肽合成定制服务，包括肥胖抑制素, β淀粉样肾脏髓质素肽, 内皮素, 内皮素拮抗剂。
详细介绍
产品咨询
California Peptide Research提供客户的多肽合成定制服务，包括肥胖抑制素, β淀粉样肾脏髓质素肽, 内皮素, 内皮素拮抗剂。
| a-Secretase Substrate | 1.0 mg | 165 |
| Acetyl-Arg-（Glu-Edans）-Val-His-His-Gln-Lys-Leu-Val-Phe-（Dabcyl-Lys）-Arg-OH | ||
| a-Secretase Substrate | 5.0 mg | 655 |
| Acetyl-Arg-（Glu-Edans）-Val-His-His-Gln-Lys-Leu-Val-Phe-（Dabcyl-Lys）-Arg-OH | ||
| Abarelix | 1.0 mg | 130 |
| Acetyl-（D-Naphtyl-Ala ）-（p-Chloro-D-Phenylalanine）-（Pyridyl-Ala）-Ser-（NMe-Tyr）-D-Asp-Leu-（Iso-Lys）-Pro-D-Ala-NH2 | ||
| Abarelix | 5.0 mg | 530 |
| Acetyl-（D-Naphtyl-Ala ）-（p-Chloro-D-Phenylalanine）-（Pyridyl-Ala）-Ser-（NMe-Tyr）-D-Asp-Leu-（Iso-Lys）-Pro-D-Ala-NH2 | ||
| Ac-Arg-Ala-Arg-AMC | 5.0 mg | 125 |
| Acetyl-Arg-Ala-Arg-AMC | ||
| Acetyl Beta Amyloid （25-35） | 1.0 mg | 55 |
| Acetyl-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH | ||
| Acetyl Beta Amyloid （25-35） | 5.0 mg | 205 |
| Acetyl-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-OH | ||
| Acetyl-Ala-Arg-AMC | 10.0 mg | 110 |
| Acetyl-Ala-Arg-AMC | ||
| Acetyl-Arg-Ala-Val-AMC | 5.0 mg | 110 |
| Acetyl-Arg-Ala-Val-AMC | ||
| Acetyl-Arg-Glu-Lys-Arg-AFC | 5.0 mg | 120 |
| Acetyl-Arg-Glu-Lys-Arg-AFC | ||
| Acetyl-Arg-Gly-Phe-Phe-Pro-AFC | 5.0 mg | 140 |
| Acetyl-Arg-Gly-Phe-Phe-Pro-AFC | ||
| Acetyl-Arg-Gly-Phe-Phe-Pro-AMC | 5.0 mg | 110 |
| Acetyl-Arg-Gly-Phe-Phe-Pro-AMC | ||
| Acetyl-Arg-Ser-Leu-Lys-AMC | 5.0 mg | 110 |
| Acetyl-Arg-Ser-Leu-Lys-AMC | ||
| Acetyl-Glu-Val-Asn-Leu-AFC | 5.0 mg | 120 |
| Acetyl-Glu-Val-Asn-Leu-AFC | ||
| Acetyl-Glu-Val-Asn-Leu-AMC | 5.0 mg | 110 |
| Acetyl-Glu-Val-Asn-Leu-AMC | ||
| Acetyl-Glu-Val-Asn-Leu-pNA | 5.0 mg | 90 |
| Acetyl-Glu-Val-Asn-Leu-pNA | ||
| Acetyl-Leu-Gln-Thr-Asp-AFC | 5.0 mg | 120 |
| Acetyl-Leu-Gln-Thr-Asp-AFC | ||
| Acetyl-Leu-Leu-Arg-AMC | 5.0 mg | 110 |
| Acetyl-Leu-Leu-Arg-AMC | ||
| Acetyl-Leu-Leu-Leu-AFC | 5.0 mg | 120 |
| Acetyl-Leu-Leu-Leu-AFC | ||
| Acetyl-Lys-Gln-Lys-Leu-Arg-4-methoxy-2-naphtylamide | 5.0 mg | 120 |
| Acetyl-Lys-Gln-Lys-Leu-Arg-4-methoxy-2-naphtylamide | ||
| Acetyl-Lys-Pro-Arg-AFC | 5.0 mg | 120 |
| Acetyl-Lys-Pro-Arg-AFC | ||
| Acetyl-Lys-Pro-Arg-AMC | 5.0 mg | 110 |
| Acetyl-Lys-Pro-Arg-AMC | ||
| Acetyl-Neurotensin （8-13） | 1.0 mg | 35 |
| Acetyl-Arg-Arg-Pro-Tyr-Ile-Leu-OH | ||
| Acetyl-Neurotensin （8-13） | 5.0 mg | 105 |
| Acetyl-Arg-Arg-Pro-Tyr-Ile-Leu-OH | ||
| Acetyl-Phe-Ile-Pro-Ala-Ser-Leu-Arg-AFC | 5.0 mg | 150 |
| Acetyl-Phe-Ile-Pro-Ala-Ser-Leu-Arg-AFC | ||
| Acetyl-Phe-Ser-Arg-pNA | 5.0 mg | 90 |
| Acetyl-Phe-Ser-Arg-pNA | ||
| Acetyl-Pro-Glu-Asp-Glu-AFC | 5.0 mg | 120 |
| Acetyl-Pro-Glu-Asp-Glu-AFC | ||
| Acetyl-Pro-Leu-Ser-Ser-Ile-Phe-Ser-Arg-Ile-Gly-Asp-Pro-Arg-Lys-Gly-Asp-Glu-Val-Asp-AFC | 5.0 mg | 185 |
| Acetyl-Pro-Leu-Ser-Ser-Ile-Phe-Ser-Arg-Ile-Gly-Asp-Pro-Arg-Lys-Gly-Asp-Glu-Val-Asp-AFC | ||
| Acetyl-Ser-Asp-Lys-Pro | 5.0 mg | 35 |
| Acetyl-Ser-Asp-Lys-Pro | ||
| Acetyl-Val-Glu-Ile-Ala-AFC | 5.0 mg | 120 |
| Acetyl-Val-Glu-Ile-Ala-AFC | ||
| ACTH （1-17） human | 1.0 mg | 80 |
| Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-OH | ||
| ACTH （1-17） human | 5.0 mg | 315 |
| Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-OH | ||
| ACTH （1-24）, human | 1.0 mg | 80 |
| Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH | ||
| ACTH （1-24）, human | 5.0 mg | 315 |
| Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-OH | ||
| ACTH （1-39）, rat | 1.0 mg | 205 |
| Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Val-Ala-Glu-Asn-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe-OH | ||
| ACTH （7-38）, human / Corticotropin Inhibiting Peptide （7-38） | 1.0 mg | 120 |
| Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-OH | ||
| ACTH （7-38）, human / Corticotropin Inhibiting Peptide （7-38） | 5.0 mg | 485 |
| Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-OH | ||
| ADAM substrate | 1.0 mg | 230 |
| （Glu-EDANS）-Lys-Pro-Ala-Lys-Phe-Phe-Arg-Leu-（Dabcyl-Lys）-NH2 | ||
| ADAM substrate | 5.0 mg | 895 |
| （Glu-EDANS）-Lys-Pro-Ala-Lys-Phe-Phe-Arg-Leu-（Dabcyl-Lys）-NH2 | ||
| Adamantaneacetyl-[DArg0,Hyp3,Thi5,8,DPhe7] Bradykinin | 1.0 mg | 60 |
| Adamataneacetyl-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Phe-Thi-Arg-OH | ||
| Adamantaneacetyl-[DArg0,Hyp3,Thi5,8,DPhe7] Bradykinin | 5.0 mg | 210 |
| Adamataneacetyl-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Phe-Thi-Arg-OH | ||
| Adrenal Secretogranin, bovine | 5.0 mg | 155 |
| Phe-Pro-Lys-Pro-Ala-Gly-Ser-Gln-Asp-Lys-Pro-Leu-His-Asn-OH | ||
| Adrenomedullin （1-50）, rat | 0.5 mg | 310 |
| Tyr-Arg-Gln-Ser-Met-Asn-Gln-Gly-Ser-Arg-Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin （1-50）, rat | 1.0 mg | 500 |
| Tyr-Arg-Gln-Ser-Met-Asn-Gln-Gly-Ser-Arg-Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin （1-52）, human | 0.5 mg | 310 |
| Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin （1-52）, human | 1.0 mg | 500 |
| Tyr-Arg-Gln-Ser-Met-Asn-Asn-Phe-Gln-Gly-Leu-Arg-Ser-Phe-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin （11-50）, rat | 0.5 mg | 230 |
| Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin （11-50）, rat | 1.0 mg | 395 |
| Ser-Thr-Gly-Cys-Arg-Phe-Gly-Thr-Cys-Thr-Met-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Gly-Met-Ala-Pro-Arg-Asn-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin （22-52）, human | 0.5 mg | 160 |
| Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Adrenomedullin （22-52）, human | 1.0 mg | 240 |
| Thr-Val-Gln-Lys-Leu-Ala-His-Gln-Ile-Tyr-Gln-Phe-Thr-Asp-Lys-Asp-Lys-Asp-Asn-Val-Ala-Pro-Arg-Ser-Lys-Ile-Ser-Pro-Gln-Gly-Tyr-NH2 | ||
| Agatoxin IVa （ SS Cys 4,20 / Cys 12,25 / Cys 19,36 / Cys 27 | 0.5 mg | 835 |
| Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly-Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala-OH | ||
| Agatoxin IVa （ SS Cys 4,20 / Cys 12,25 / Cys 19,36 / Cys 27 | 1.0 mg | 1525 |
| Lys-Lys-Lys-Cys-Ile-Ala-Lys-Asp-Tyr-Gly-Arg-Cys-Lys-Trp-Gly-Gly-Thr-Pro-Cys-Cys-Arg-Gly-Arg-Gly-Cys-Ile-Cys-Ser-Ile-Met-Gly-Thr-Asn-Cys-Glu-Cys-Lys-Pro-Arg-Leu-Ile-Met-Glu-Gly-Leu-Gly-Leu-Ala-OH | ||
| Akt Substrate | 5.0 mg | 105 |
| Arg-Pro-Arg-Ala-Ala-Thr-Phe-NH2 | ||
| All D Beta Amyloid （1-40）, human | 0.5 mg | 395 |
| D-Asp-D-Ala-D-Glu-D-Phe-D-Arg-D-His-D-Asp-D-Ser-Gly-D-Tyr-D-Glu-D-Val-D-His-D-His-D-Gln-D-Lys-D-Leu-D-Val-D-Phe-D-Phe-D-Ala-D-Glu-D-Asp-D-Val-Gly-D-Ser-D-Asn-D-Lys-Gly-D-Ala-D-Ile-D-Ile-Gly-D-Leu-D-Met-D-Val-Gly-Gly-D-Val-D-Val-OH | ||
| All D Beta Amyloid （1-40）, human | 1.0 mg | 685 |
| D-Asp-D-Ala-D-Glu-D-Phe-D-Arg-D-His-D-Asp-D-Ser-Gly-D-Tyr-D-Glu-D-Val-D-His-D-His-D-Gln-D-Lys-D-Leu-D-Val-D-Phe-D-Phe-D-Ala-D-Glu-D-Asp-D-Val-Gly-D-Ser-D-Asn-D-Lys-Gly-D-Ala-D-Ile-D-Ile-Gly-D-Leu-D-Met-D-Val-Gly-Gly-D-Val-D-Val-OH | ||
| Allatostatin B2, cockroach | 1.0 mg | 105 |
| Ala-Tyr-Ser-Tyr-Val-Ser-Glu-Tyr-Lys-Arg-Leu-Pro-Val-Tyr-Asn-Phe-Gly-Leu-NH2 | ||
| Alpha Atrial Natriuretic Polypeptide （1-28）, human / ANP （1- | 0.5 mg | 125 |
| Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| Alpha Atrial Natriuretic Polypeptide （1-28）, human / ANP （1- | 1.0 mg | 205 |
| Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| Alpha MSH Ac-Nle4 c[Asp5, D-Phe7, Lys10] （4-10） amide | 1.0 mg | 60 |
| Acetyl-050-Asp-His-011-Arg-Trp-Lys-NH2 | ||
| Alpha MSH Ac-Nle4 c[Asp5, D-Phe7, Lys10] （4-10） amide | 5.0 mg | 215 |
| Acetyl-050-Asp-His-011-Arg-Trp-Lys-NH2 | ||
|
Alpha MSH [D-Phe7]
|
1.0 mg | 60 |
| Acetyl-Ser-Tyr-Ser-Met-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
| Alpha MSH [D-Phe7] | 5.0 mg | 215 |
| Acetyl-Ser-Tyr-Ser-Met-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
| Alpha MSH [Nle4,D-Phe7] | 1.0 mg | 60 |
| Acetyl-Ser-Tyr-Ser-050-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
| Alpha MSH [Nle4,D-Phe7] | 5.0 mg | 215 |
| Acetyl-Ser-Tyr-Ser-050-Glu-His-011-Arg-Trp-Gly-Lys-Pro-Val-NH2 | ||
| Alpha MSH, Ac-NLe4c[Asp5,DNal7,Lys10]（4-10） amide | 1.0 mg | 60 |
| Acetyl-050-Asp-His-038-Arg-Trp-Lys-NH2 | ||
| Alpha MSH, Ac-NLe4c[Asp5,DNal7,Lys10]（4-10） amide | 5.0 mg | 215 |
| Acetyl-050-Asp-His-038-Arg-Trp-Lys-NH2 | ||
| Amylin （1-37） NH2, human / Islet Amyloid Polypeptide （IAPP）, | 1.0 mg | 295 |
| Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
| Amylin （1-37） NH2, human / Islet Amyloid Polypeptide （IAPP）, | 5.0 mg | 1315 |
| Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
| Amylin （1-37） NH2, human / Islet Amyloid Polypeptide （IAPP）, | 10.0 mg | 2520 |
| Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
| Amylin, rat | 0.5 mg | 135 |
| Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
| Amylin, rat | 1.0 mg | 230 |
| Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-Arg-Ser-Ser-Asn-Asn-Leu-Gly-Pro-Val-Leu-Pro-Pro-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr-NH2 | ||
| Amyloid Blocker | 5.0 mg | 85 |
| Acetyl-Gln-Lys-Leu-Val-Phe-Phe-NH2 | ||
| Amyloid fragment （Pro18,Asp21） （17-21） | 5.0 mg | 105 |
| Leu-Pro-Phe-Phe-Asp-OH | ||
| Amyloid precursor | 1.0 mg | 135 |
| Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-（DNP-Lys）-Arg-Arg-NH2 | ||
| Amyloid precursor | 5.0 mg | 525 |
| Mca-Ser-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Arg-（DNP-Lys）-Arg-Arg-NH2 | ||
| Angiotensin Fragment （ 1-7 ） Acetate | 5.0 mg | 55 |
| Asp-Arg-Val-Tyr-Ile-His-Pro-OH | ||
| Angiotensin I [Asn1,Val5,Asn9], salmon | 1.0 mg | 30 |
| Asn-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
| Angiotensin I [Asn1,Val5,Asn9], salmon | 5.0 mg | 105 |
| Asn-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
| Angiotensin I [Val5,Asn9], bullfrog | 1.0 mg | 30 |
| Asp-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
| Angiotensin I [Val5,Asn9], bullfrog | 5.0 mg | 105 |
| Asp-Arg-Val-Tyr-Val-His-Pro-Phe-Asn-Leu-OH | ||
| Angiotensin I/II （1-5） | 1.0 mg | 45 |
| Asp-Arg-Val-Tyr-Ile-OH | ||
| Angiotensin II [Sar1,Ile8] | 1.0 mg | 30 |
| 034-Arg-Val-Tyr-Ile-His-Pro-Ile-OH | ||
| Angiotensin II [Sar1,Ile8] | 5.0 mg | 100 |
| 034-Arg-Val-Tyr-Ile-His-Pro-Ile-OH | ||
| Angiotensin II, human | 5.0 mg | 35 |
| Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-OH | ||
| Angiotensin II-[Sar1] | 5.0 mg | 80 |
| 034-Arg-Val-Tyr-Ile-His-Pro-Phe-OH | ||
| Angiotensin III, human） / Angiotensin II-[Des Asp1] | 10.0 mg | 55 |
| Arg-Val-Tyr-Ile-His-Pro-Phe-OH | ||
| Angiotensinogen （1-14） Renin Substrate （porcine） | 1.0 mg | 40 |
| Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser-OH | ||
| Angiotensinogen （1-14） Renin Substrate （porcine） | 10.0 mg | 185 |
| Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-Leu-Val-Tyr-Ser-OH | ||
| ANP （123-150）, rat / ANP （6-33）, rat / ANP （1-28）, rat | 0.5 mg | 125 |
| Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| ANP （123-150）, rat / ANP （6-33）, rat / ANP （1-28）, rat | 1.0 mg | 205 |
| Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| ANP （126-150）, rat / Auriculin B, ANP （4-28）, rat | 0.5 mg | 125 |
| Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| ANP （126-150）, rat / Auriculin B, ANP （4-28）, rat | 1.0 mg | 205 |
| Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| ANP （4-24）, frog | 1.0 mg | 165 |
| Cys-Phe-Gly-Ser-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Met-Gly-Cys-Gly-Arg-Arg-Phe-OH | ||
| ANP Des[18-22] （4-23） amide, rat | 1.0 mg | 125 |
| Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Cys-NH2 | ||
| Antennapedia Peptide | 1.0 mg | 80 |
| Arg – Gln – Ile – Lys – Ile – Trp – Phe – Gln – Asn – Arg – Arg – Met – Lys – Trp – Lys – Lys | ||
| Apamin, bee venom （SS1-11）（SS3-15） | 0.5 mg | 105 |
| Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu-Cys-Ala-Arg-Arg-Cys-Gln-Gln-His-NH2 | ||
| Apamin, bee venom （SS1-11）（SS3-15） | 1.0 mg | 160 |
| Cys-Asn-Cys-Lys-Ala-Pro-Glu-Thr-Ala-Leu-Cys-Ala-Arg-Arg-Cys-Gln-Gln-His-NH2 | ||
| APP （354-371） | 1.0 mg | 135 |
| Lys-Ala-Val-Ile-Gln-His-Phe-Gln-Glu-Lys-Val-Glu-Ser-Leu-Glu-Gln-Glu-Ala-OH | ||
| APP （354-371） | 5.0 mg | 525 |
| Lys-Ala-Val-Ile-Gln-His-Phe-Gln-Glu-Lys-Val-Glu-Ser-Leu-Glu-Gln-Glu-Ala-OH | ||
| APP Beta Secretase Inhibitor | 1.0 mg | 160 |
| Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-200-Val-Ala-Glu-Phe-OH | ||
| APP gamma secretase inhibitor | 5.0 mg | 60 |
| 3-5 difluorophenacetyl-Ala-217-t-Butylester | ||
| APP gamma secretase inhibitor | 5.0 mg | 60 |
| 3-5 difluorophenacetyl-Ala-（S-Phenylglycine）-Methylester | ||
| Arg-Glu（EDANS）-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-（e-Dabcyl-Lysine）-Arg-OH | 1.0 mg | 135 |
| Arg-Glu（EDANS）-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-（e-Dabcyl-Lysine）-Arg-OH | ||
| Arg-Leu-Lys-Gly-Gly-AFC | 5.0 mg | 140 |
| Arg-Leu-Lys-Gly-Gly-AFC | ||
| Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-OH | 5.0 mg | 120 |
| Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-OH | ||
| Asp-Glu-Val-Asp-AFC | 5.0 mg | 120 |
| Asp-Glu-Val-Asp-AFC | ||
| Atriopeptine III, rat;ANP （127-150）, rat | 0.5 mg | 115 |
| Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| Atriopeptine III, rat;ANP （127-150）, rat | 1.0 mg | 185 |
| Ser-Ser-Cys-Phe-Gly-Gly-Arg-Ile-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH | ||
| Autocamptide-2 Related Inhibitoy Peptide | 5.0 mg | 105 |
| Lys-Lys-Ala-Leu-Arg-Arg-Gln-Glu-Ala-Val-Asp-Ala-Leu-OH | ||
| Autocamptide-2 Related Inhibitoy Peptide | 5.0 mg | 105 |
| Myristoyl-Lys-Lys-Ala-Leu-Arg-Arg-Gln-Glu-Ala-Val-Asp-Ala-Leu-OH | ||
| BAM （6-22） Quote : 6920 | 0.5 mg | 125 |
| Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-OH | ||
| BAM （6-22） Quote : 6920 | 1.0 mg | 185 |
| Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-OH | ||
| BAM 3200 Bovine Adrenal Medulla Peptide E | 0.5 mg | 175 |
| Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-OH | ||
| BAM 3200 Bovine Adrenal Medulla Peptide E | 1.0 mg | 290 |
| Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-OH | ||
| Beta Amyloid （1-16） [Gln11], human | 0.5 mg | 60 |
| Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-OH | ||
| Beta Amyloid （1-16） [Gln11], human | 1.0 mg | 85 |
| Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-OH | ||
| Beta Amyloid （1-16） [Gln11], human | 5.0 mg | 320 |
| Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-OH | ||
| Beta Amyloid （1-16）, rat | 1.0 mg | 90 |
| Asp-Ala-Glu-Phe-Gly-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Gln-Lys-OH | ||
| Beta Amyloid （1-16）, rat | 5.0 mg | 340 |
| Asp-Ala-Glu-Phe-Gly-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Gln-Lys-OH | ||
| Beta Amyloid （1-28）, [Gln11], human | 0.5 mg | 95 |
| Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Gln-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-OH | ||